Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Apr 29, 2023 4:59pm
112 Views
Post# 35421110

RE:GUD will follow soon

RE:GUD will follow soon Oh my ... not only is your understanding of GUD a little troubling, you also don't know what happened to ENDO.

Let me assist ...
1.  Endo took on way too much debt in trying to get bigger - guessing shareholders demanded quick growth and that's what taking on debt allowed them to do.
2.  Endo had a variety of lawsuits to deal with.
3.  Endo had some patent and patent cliff issues it didn't prepare for.
4.  And finally, to my delight, they gave up on growing Paladin as a ROW.  It was too much work for them.

I don't want competition in the ROW space (as a Knight investor).  That is the advantage that I bought into.

Do I care if we have losses?  Not if it's coming from amortizations and depreciations.  I can handle not paying taxes.  I'm OK with that.

What were our sales in 2015?  $300K or so.
What were our sales in 2022?  more than $290 MM.
How much cash to we have coming into the bank each year?  $40 MM.
How much cash?  $150 MM
How much in investments?  $170 MM

So, when are we going under?

Hahaha !

Come on man.  Just enjoy the price !  What do you care if it's a buyer's market?  You're neither a buyer or a seller.  Just a lonely sole looking for some loving.  I'll give you some loving !!!

: )
<< Previous
Bullboard Posts
Next >>